Regeneron Beats Q1 Estimates on Strong Dupixent Demand
Regeneron posted Q1 profit of $9.47 per share as Dupixent sales rose 33 percent. The firm also authorized a new $3 billion share repurchase program.
Xurve View
Insights:
Xurve View
REGENERON PHARMACEUTICALS reported first-quarter adjusted profit of $9.47 per share on Wednesday morning, beating the $8.94 average analyst estimate. Total revenue rose to $3.61 billion, surpassing the $3.49 billion expected by LSEG data. The results signal a successful pivot toward high-growth immunology and oncology treatments as the company defends its core ophthalmology franchise.
